Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590911 | 0.96 | SLC10A2 (0.54) | SLC10A2 | |
| SCHEMBL2586789 | 0.96 | SLC10A2 (0.54) | SLC10A2 | |
| SCHEMBL2582109 | 0.92 | SLC10A2 (0.63) | SLC10A2 | |
| SCHEMBL2581999 | 0.92 | SLC10A2 (0.63) | SLC10A2 | |
| SCHEMBL7472527 | 0.92 | SLC10A2 (0.63) | SLC10A2 | |
| SCHEMBL7472523 | 0.92 | SLC10A2 (0.63) | SLC10A2 | |
| SCHEMBL8798740 | 0.92 | SLC10A2 (0.47) | SLC10A2 | |
| SCHEMBL2586730 | 0.88 | SLC10A2 (0.59) | SLC10A2 | |
| SCHEMBL1388965 | 0.87 | SLC10A2 (0.54) | SLC10A2 | |
| SCHEMBL2589578 | 0.87 | SLC10A2 (0.57) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186558-B2 | Synthetic methods | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-11-30 | — | — | US | disclosed |
| EP-3475266-A1 | SYNTHETIC METHODS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2019-05-01 | — | — | EP | disclosed |
| WO-2018002827-A1 | SYNTHETIC METHODS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-01-04 | — | — | WO | disclosed |
| EP-3177600-A1 | SYNTHESIS OF BENZOTHIAZEPINES | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-06-14 | — | — | EP | disclosed |
| EP-2563122-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2016020785-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-02-11 | — | — | WO | disclosed |
| EP-2968230-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968262-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015065983-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS | Lumena Pharmaceuticals, Inc. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2014144485-A9 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014144485-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144650-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2771003-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | Lumena Pharmaceuticals, Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2770990-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2739286-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PANCREATITIS | Lumena Pharmaceuticals, Inc. (US) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013063512-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS, INC (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013063526-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-2563122-A1 | CHEMICAL COMPOUNDS | Glaxosmithkline LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2013020108-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PANCREATITIS | Lumena Pharmaceuticals, Inc. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2011137135-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186558-B2 | Synthetic methods | SLC10A1, GYS2, CYP7A1 | SLC10A2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.